Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Myeloid Cell Origins, Differentiation, and Clinical Implications.

Weiskopf K, Schnorr PJ, Pang WW, Chao MP, Chhabra A, Seita J, Feng M, Weissman IL.

Microbiol Spectr. 2016 Oct;4(5). doi: 10.1128/microbiolspec.MCHD-0031-2016.

PMID:
27763252
2.

RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML.

Crews LA, Balaian L, Delos Santos NP, Leu HS, Court AC, Lazzari E, Sadarangani A, Zipeto MA, La Clair JJ, Villa R, Kulidjian A, Storb R, Morris SR, Ball ED, Burkart MD, Jamieson CH.

Cell Stem Cell. 2016 Nov 3;19(5):599-612. doi: 10.1016/j.stem.2016.08.003.

PMID:
27570067
3.

Polycomb complex PRC1 as gatekeeper of intestinal stem cell identity.

Léveillé N, Vermeulen L.

Stem Cell Investig. 2016 Jun 15;3:22. doi: 10.21037/sci.2016.06.03.

4.

ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.

Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L, Chun HJ, Pineda G, Morris SR, Mason CN, Geron I, Barrett C, Goff DJ, Wall R, Pellecchia M, Minden M, Frazer KA, Marra MA, Crews LA, Jiang Q, Jamieson CH.

Cell Stem Cell. 2016 Aug 4;19(2):177-91. doi: 10.1016/j.stem.2016.05.004.

PMID:
27292188
5.

Wnt Signaling: Role in Regulation of Haematopoiesis.

Undi RB, Gutti U, Sahu I, Sarvothaman S, Pasupuleti SR, Kandi R, Gutti RK.

Indian J Hematol Blood Transfus. 2016 Jun;32(2):123-34. doi: 10.1007/s12288-015-0585-3. Review.

PMID:
27065573
6.

Tracking of Normal and Malignant Progenitor Cell Cycle Transit in a Defined Niche.

Pineda G, Lennon KM, Delos Santos NP, Lambert-Fliszar F, Riso GL, Lazzari E, Marra MA, Morris S, Sakaue-Sawano A, Miyawaki A, Jamieson CH.

Sci Rep. 2016 Apr 4;6:23885. doi: 10.1038/srep23885.

7.

Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.

Holm F, Hellqvist E, Mason CN, Ali SA, Delos-Santos N, Barrett CL, Chun HJ, Minden MD, Moore RA, Marra MA, Runza V, Frazer KA, Sadarangani A, Jamieson CH.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15444-9. doi: 10.1073/pnas.1506943112.

8.

Evolution of normal and neoplastic tissue stem cells: progress after Robert Hooke.

Weissman I.

Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20140364. doi: 10.1098/rstb.2014.0364. Review.

9.

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.

Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, O'Hare T, Deininger MW.

Leukemia. 2015 Dec;29(12):2328-37. doi: 10.1038/leu.2015.196.

10.

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.

Mancini M, Leo E, Takemaru K, Campi V, Castagnetti F, Soverini S, De Benedittis C, Rosti G, Cavo M, Santucci MA, Martinelli G.

PLoS One. 2015 Jul 6;10(7):e0131074. doi: 10.1371/journal.pone.0131074.

11.

Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells.

Kabiri Z, Numata A, Kawasaki A, Edison, Tenen DG, Virshup DM.

Blood. 2015 Aug 27;126(9):1086-94. doi: 10.1182/blood-2014-09-598540.

12.

Clinicopathological significance of wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma.

Deng F, Zhou K, Cui W, Liu D, Ma Y.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):3045-53.

13.

GLI2 inhibition abrogates human leukemia stem cell dormancy.

Sadarangani A, Pineda G, Lennon KM, Chun HJ, Shih A, Schairer AE, Court AC, Goff DJ, Prashad SL, Geron I, Wall R, McPherson JD, Moore RA, Pu M, Bao L, Jackson-Fisher A, Munchhof M, VanArsdale T, Reya T, Morris SR, Minden MD, Messer K, Mikkola HK, Marra MA, Hudson TJ, Jamieson CH.

J Transl Med. 2015 Mar 21;13:98. doi: 10.1186/s12967-015-0453-9.

14.

An RNA editing fingerprint of cancer stem cell reprogramming.

Crews LA, Jiang Q, Zipeto MA, Lazzari E, Court AC, Ali S, Barrett CL, Frazer KA, Jamieson CH.

J Transl Med. 2015 Feb 12;13:52. doi: 10.1186/s12967-014-0370-3.

15.

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.

Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN.

Leukemia. 2015 Jun;29(6):1267-78. doi: 10.1038/leu.2014.340.

16.

A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1.

Tsai BP, Jimenez J, Lim S, Fitzgerald KD, Zhang M, Chuah CT, Axelrod H, Wilson L, Ong ST, Semler BL, Waterman ML.

Open Biol. 2014 Nov;4(11):140180. doi: 10.1098/rsob.140180.

17.

Multiple alternative splicing and differential expression pattern of the glycogen synthase kinase-3β (GSK3β) gene in goat (Capra hircus).

Hou Y, Wang Y, Wang Y, Zhong T, Li L, Zhang H, Wang L.

PLoS One. 2014 Oct 15;9(10):e109555. doi: 10.1371/journal.pone.0109555.

18.

GSK3 protein positively regulates type I insulin-like growth factor receptor through forkhead transcription factors FOXO1/3/4.

Huo X, Liu S, Shao T, Hua H, Kong Q, Wang J, Luo T, Jiang Y.

J Biol Chem. 2014 Sep 5;289(36):24759-70. doi: 10.1074/jbc.M114.580738.

19.

Breast cancer stem cells: Multiple capacities in tumor metastasis.

Geng SQ, Alexandrou AT, Li JJ.

Cancer Lett. 2014 Jul 10;349(1):1-7. doi: 10.1016/j.canlet.2014.03.036. Review.

20.

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Tenen DG, Stone RM, Griffin JD.

Blood. 2014 May 1;123(18):2816-25. doi: 10.1182/blood-2013-02-481507.

Items per page

Supplemental Content

Support Center